Evidence map›Paper›PMID 41734182›Full record

ArticlePLOS digital health2026

Design, implementation and analysis of a quality assurance process for Informed Consents using the DZHK registry TORCH-DZHK1 as an example.

Dana Stahl, Katrin Leyh, Alexander Rudolph, Arne Blumentritt, Kerstin Weitmann, Monika Kraus, Johannes Trebing, Julia Hoffmann, Farbod Sedaghat-Hamedani, Benjamin Meder and 1 more

Abstract read
In one paragraph

Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dana StahlTrusted Third Party of the University Medicine Greifswald, Ellernholzstraße, Greifswald, Germany.ORCID https://orcid.org/0000-0002-4283-4543
Katrin LeyhTrusted Third Party of the University Medicine Greifswald, Ellernholzstraße, Greifswald, Germany.
Alexander RudolphTrusted Third Party of the University Medicine Greifswald, Ellernholzstraße, Greifswald, Germany.
Arne BlumentrittTrusted Third Party of the University Medicine Greifswald, Ellernholzstraße, Greifswald, Germany.
Kerstin WeitmannInstitute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Ellernholzstraße, Greifswald, Germany.
Monika KrausInstitute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Johannes TrebingInstitute for Cardiomyopathies Heidelberg (CFH.), Department of Medicine Trial Unit, Clinic for Cardiology, Angiology and Pneumology of III, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0009-0001-8872-6935
Julia HoffmannDZHK (German Centre for Cardiovascular Research), Main Office, Berlin, Germany.
Farbod Sedaghat-HamedaniInstitute for Cardiomyopathies Heidelberg (CFH.), Department of Medicine Trial Unit, Clinic for Cardiology, Angiology and Pneumology of III, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-3266-0527
Benjamin MederInstitute for Cardiomyopathies Heidelberg (CFH.), Department of Medicine Trial Unit, Clinic for Cardiology, Angiology and Pneumology of III, University Hospital Heidelberg, Heidelberg, Germany.
Wolfgang HoffmannInstitute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Ellernholzstraße, Greifswald, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To collect sensitive patient data during clinical trials, the Informed Consent (IC) of the participants must be obtained beforehand. If the IC is not correct and complete, the document cannot be used to represent the will of the participant and will not be considered a legally valid document. However, few studies have examined the quality of the IC and the IC-quality found is unfortunately not satisfactory. The aim of this article is to describe the development of an IC quality assurance concept and to report the results of an evaluation using the example of a German Centre for Cardiovascular Research (DZHK) registry. All quality issues identified during the study were documented. These were aggregated into the quality indicators "Completeness", "Consistency of Data", "Correctness" and "Validity". Of 2,453 ICs, 1,588 had at least one quality issue; 99.8% of them were resolved. In addition, training sessions were conducted with study staff to raise awareness of the importance of correct IC collection, including documentation, and to minimize quality issues. Our data exemplify that improvements in the recording of ICs by the study staff can be achieved. This evaluation shows the value and importance of continuous IC quality control.

Identifiers

PMID41734182
PMCPMC12931750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.